Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$12.63 USD
-0.37 (-2.85%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $12.59 -0.04 (-0.32%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Cidara Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 64 | 64 | 50 | 12 | 21 |
Cost Of Goods | 2 | 0 | 0 | 0 | 0 |
Gross Profit | 62 | 64 | 50 | 12 | 21 |
Selling & Adminstrative & Depr. & Amort Expenses | 87 | 94 | 92 | 84 | 63 |
Income After Depreciation & Amortization | -24 | -30 | -42 | -72 | -42 |
Non-Operating Income | 2 | 0 | 0 | 0 | 1 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | -22 | -30 | -42 | -72 | -41 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -23 | -30 | -42 | -72 | -41 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -23 | -30 | -42 | -72 | -41 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -24 | -28 | -43 | -72 | -41 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | -1 | 0 | 0 |
Income After Depreciation & Amortization | -24 | -30 | -42 | -72 | -42 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 69.86 | 52.45 | 41.56 | 29.09 |
Diluted EPS Before Non-Recurring Items | -99,999.00 | -0.43 | -0.81 | -1.80 | -1.41 |
Diluted Net EPS (GAAP) | -0.26 | -0.43 | -0.81 | -1.80 | -1.41 |
Fiscal Year end for Cidara Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 17.58 | 12.72 | 7.61 | 25.99 |
Cost Of Goods | NA | 1.14 | 0.39 | 0.00 | 0.00 |
Gross Profit | NA | 16.45 | 12.33 | 7.61 | 25.99 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 22.52 | 20.89 | 20.45 | 23.02 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -6.07 | -8.56 | -12.84 | 2.97 |
Non-Operating Income | NA | 0.76 | 0.61 | 0.62 | 0.00 |
Interest Expense | NA | NA | 0.00 | 0.00 | -0.23 |
Pretax Income | NA | -5.55 | -7.94 | -12.21 | 3.21 |
Income Taxes | NA | 0.06 | 0.23 | 0.15 | 0.00 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.61 | -8.17 | -12.36 | 3.21 |
Extras & Discontinued Operations | NA | NA | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.61 | -8.17 | -12.36 | 3.21 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 90.29 | 90.12 | 101.19 |
Diluted EPS Before Non-Recurring Items | -99,999.00 | -99,999.00 | -0.09 | -0.14 | 0.03 |
Diluted Net EPS (GAAP) | -99,999.00 | -0.06 | -0.09 | -0.14 | 0.03 |